Get breaking news alerts via email

Click here to manage your alerts
European study of pancreatic cancer to use Utah equipment
Treatment » BSD Medical’s hyperthermia system enters next phase of clinical trials.
First Published Feb 21 2012 09:42 am • Last Updated Feb 22 2012 08:54 pm

Utah’s BSD Medical said a new clinical study is being launched in Europe to further measure the benefits of combining the use of hyperthermia with chemotherapy for the treatment of pancreatic cancer.

The study, which will be carried out at four sites in Germany, will compare using chemotherapy combined with BSD’s heat-treatment system to using chemotherapy alone.

Join the Discussion
Post a Comment

BSD said the Phase III study is being sponsored by the European Society for Hyperthermic Oncology.

The Utah company said an earlier Phase II study that used chemotherapy and hyperthermia to treat 21 inoperable pancreatic cancer patients produced an overall patient survival rate of 16.9 months versus six months using chemotherapy alone.

The difference between a Phase II and Phase III study is that in the later patients will be assigned to the two treatment groups at random, said Dixie Sells, vice president of regulatory affairs at BSD Medical. "A Phase III study is considered the gold standard for clinical research."

The study is scheduled to open for patient enrollment on April 1. Researchers will be accepting patients from the United States, but they will have to travel to Germany for treatment, Sells said.

The coordinating investigator will be Rolf D. Issls, a doctor with the Department of Medical Oncology at the Munich University Medical School in Germany.

BSD Medical, whose shares are listed on the Nasdaq stock market and are trading in the $2.50 range, manufacturers hyperthermia systems that treat cancers using heat that is produced from focused radio-frequency and microwave energy.


Twitter: @OberbeckBiz

story continues below

Copyright 2014 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Top Reader Comments Read All Comments Post a Comment
Click here to read all comments   Click here to post a comment

About Reader Comments

Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Staying Connected
Contests and Promotions
  • Search Obituaries
  • Place an Obituary

  • Search Cars
  • Search Homes
  • Search Jobs
  • Search Marketplace
  • Search Legal Notices

  • Other Services
  • Advertise With Us
  • Subscribe to the Newspaper
  • Access your e-Edition
  • Frequently Asked Questions
  • Contact a newsroom staff member
  • Access the Trib Archives
  • Privacy Policy
  • Missing your paper? Need to place your paper on vacation hold? For this and any other subscription related needs, click here or call 801.204.6100.